These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2547626)

  • 1. Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist.
    Yamada K; Imai M; Yoshida S
    Eur J Pharmacol; 1989 Jan; 160(2):229-37. PubMed ID: 2547626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analgesic and discriminative stimulus properties of U-62,066E, the selective kappa-opioid receptor agonist, in the rat.
    Ohno M; Yamamoto T; Ueki S
    Psychopharmacology (Berl); 1992; 106(1):31-8. PubMed ID: 1346721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diuretic actions in man of a selective kappa opioid agonist: U-62,066E.
    Peters GR; Ward NJ; Antal EG; Lai PY; deMaar EW
    J Pharmacol Exp Ther; 1987 Jan; 240(1):128-31. PubMed ID: 3027300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of elevated arginine vasopressin secretion in response to osmotic stimulation and acute haemorrhage by U-62066E, a kappa-opioid receptor agonist.
    Yamada K; Nakano M; Yoshida S
    Br J Pharmacol; 1990 Feb; 99(2):384-8. PubMed ID: 2158377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective cardiovascular and neuroendocrine effects of a kappa-opioid agonist in the nucleus tractus solitarii of rats.
    Carter DA; Lightman SL
    J Physiol; 1985 Oct; 367():363-75. PubMed ID: 2997441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further study of kappa opioids on increased urination.
    Leander JD
    J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitussive effects of two specific kappa-opioid agonists, U-50,488H and U-62,066E, in rats.
    Kamei J; Tanihara H; Kasuya Y
    Eur J Pharmacol; 1990 Oct; 187(2):281-6. PubMed ID: 2272363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
    Pugsley MK; Penz WP; Walker MJ; Wong TM
    Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa agonist-induced diuresis: evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels.
    Leander JD; Hart JC; Zerbe RL
    J Pharmacol Exp Ther; 1987 Jul; 242(1):33-9. PubMed ID: 3039112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. kappa-Opioid receptor agonist protects against ischemic reduction of 2-deoxyglucose uptake in morphine-tolerant rats.
    Shibata S; Tominaga K; Watanabe S
    Eur J Pharmacol; 1995 Jun; 279(2-3):197-202. PubMed ID: 7556401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of kappa-mediated antitussive activity in rats by a delta-agonist.
    Kamei J; Tanihara H; Kasuya Y
    Res Commun Chem Pathol Pharmacol; 1992 Jun; 76(3):375-8. PubMed ID: 1321982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of diuretic action of spiradoline (U-62066E)--a kappa opioid receptor agonist in the human.
    Rimoy GH; Bhaskar NK; Wright DM; Rubin PC
    Br J Clin Pharmacol; 1991 Nov; 32(5):611-5. PubMed ID: 1659438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488.
    Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
    Neuroendocrinology; 1986; 42(1):82-7. PubMed ID: 3001566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different motor actions of dynorphins and nonpeptide kappa opioid receptor agonists in the isolated rat colon.
    Scheurer U; Wenger F; Caliezi A; Drack E; Varga L; Halter F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1324-30. PubMed ID: 1969475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites.
    Rossi NF; Brooks DP
    Am J Physiol; 1996 Feb; 270(2 Pt 1):E367-72. PubMed ID: 8779961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kappa-opioid peptide receptor stimulation increases cytosolic pH and myofilament responsiveness to Ca2+ in cardiac myocytes.
    Ventura C; Capogrossi MC; Spurgeon HA; Lakatta EG
    Am J Physiol; 1991 Nov; 261(5 Pt 2):H1671-4. PubMed ID: 1659231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of aquaporin-2 abundance in microdissected collecting ducts: axial distribution and control by AVP.
    Kishore BK; Terris JM; Knepper MA
    Am J Physiol; 1996 Jul; 271(1 Pt 2):F62-70. PubMed ID: 8760244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin-1 inhibits AVP-stimulated osmotic water permeability in rat inner medullary collecting duct.
    Oishi R; Nonoguchi H; Tomita K; Marumo F
    Am J Physiol; 1991 Dec; 261(6 Pt 2):F951-6. PubMed ID: 1661085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Study on the mechanism of U50488H-induced diuresis.
    Oiso Y; Iwasaki Y; Kondo K; Takatsuki K; Tomita A
    Neuroendocrinology; 1988 Dec; 48(6):658-62. PubMed ID: 3251164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kappa agonists and vasopressin secretion.
    Hamon G; Jouquey S
    Horm Res; 1990; 34(3-4):129-32. PubMed ID: 1966562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.